Xenetic Biosciences, Inc.
XBIO· Nasdaq
XBIOXenetic Biosciences, Inc.
Filed May 12, 2026 · 10-Q · 42 days after period end · 0001683168-26-003727
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $806.92K | $593.26K | $510.82K | $605.84K |
| Net Income | -$456.38K | -$903.14K | -$1.20M | -$856.55K |
| EPS Diluted | -$0.20 | -$0.59 | -$0.78 | -$0.56 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 12, 2026 · 42 d after period end
